Results 1 to 10 of about 423,855 (249)

A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life [PDF]

MAbs, 2015
Immunoglobulin G (IgG) has an unusually long serum half-life in comparison to proteins of a similar size. It is well-known that this phenomenon is due to IgG's ability to bind the neonatal Fc receptor (FcRn) in a pH-dependent manner. FcRn binding properties can vary among IgGs, resulting in altered in vivo half-lives, and therefore it would be ...
Andrew R Crowley, Mark S Klempner
exaly   +3 more sources

Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies

Research and Practice in Thrombosis and Haemostasis, 2023
Extended half-life recombinant FVIII products (EHL-rFVIIIs) have been engineered to improve the pharmacokinetic profile of FVIII, enabling better hemostatic protection with a reduced number of injections in persons with hemophilia. Previous studies showed several discrepancies in FVIII activity (FVIII:C) measurements for EHL-rFVIIIs comparing one-stage
Maria Elisa Mancuso, Raimondo De Cristofaro, Stefano Lancellotti   +2 more
exaly   +3 more sources

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo [PDF]

mAbs, 2021
Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin.
Simone Mester, Mitchell Evers, Saskia Meyer, Jeannette Nilsen, Victor Greiff, Inger Sandlie, Jeanette Leusen, Jan Terje Andersen   +7 more
doaj   +7 more sources

Evaluation of Alectinib Metabolic Stability in HLMs Using Fast LC-MS/MS Method: In Silico ADME Profile, P450 Metabolic Lability, and Toxic Alerts Screening

Pharmaceutics, 2023
Alectinib, also known as Alecensa®, is prescribed for the therapeutic treatment of individuals diagnosed with metastatic non-small cell lung cancer (NSCLC) who have a specific genetic mutation referred to as anaplastic lymphoma kinase (ALK) positivity ...
Mohamed W. Attwa, Haitham AlRabiah, Gamal A. E. Mostafa, Adnan A. Kadi   +3 more
doaj   +1 more source

Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method

Molecules, 2023
Selpercatinib (SLP; brand name Retevmo®) is a selective and potent RE arranged during transfection (RET) inhibitor. On 21 September 2022, the FDA granted regular approval to SLP (Retevmo, Eli Lilly, and Company).
Mohamed W. Attwa, Haitham AlRabiah, Gamal A.E. Mostafa, Ahmed H. Bakheit, Adnan A. Kadi   +4 more
doaj   +1 more source

Formation, Structural Characterization, and Functional Properties of Corn Starch/Zeaxanthin Composites

Foods, 2023
Zeaxanthin is a natural xanthophyll carotenoid and the main macular pigment that protects the macula from light-initiated oxidative damage, but it has poor stability and low bioavailability.
Songnan Li, Duo Feng, Enpeng Li, Robert G. Gilbert   +3 more
doaj   +1 more source

A Fast LC-MS/MS Methodology for Estimating Savolitinib in Human Liver Microsomes: Assessment of Metabolic Stability Using In Vitro Metabolic Incubation and In Silico Software Analysis

Separations, 2023
Savolitinib (Orpathys®), was developed by (HUTCHMED (Shanghai, China) and, AstraZeneca (Gaithersburg, Maryland, USA), is an inhibitor of the c-Met receptor tyrosine kinase that is orally bioavailable.
Mohamed W. Attwa, Haitham AlRabiah, Ali S. Abdelhameed, Adnan A. Kadi   +3 more
doaj   +1 more source

Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation

Molecules, 2023
Sapitinib (AZD8931, SPT) is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) family (pan-erbB). In multiple tumor cell lines, STP has been shown to be a much more potent inhibitor of EGF-driven cellular proliferation than ...
Mohamed W. Attwa, Haitham AlRabiah, Gamal A. E. Mostafa, Adnan A. Kadi   +3 more
doaj   +1 more source

A Sensitive, Green, and Fast LC–MS/MS Analytical Method for the Quantification of Ribociclib: Evaluation of the Metabolic Stability in HLMs

Separations, 2023
Ribociclib (Kisqali®) is a pharmacological agent that has great selectivity as a cyclin-dependent kinase 4/6 inhibitor. It has received regulatory approval for its application in the treatment of breast cancer.
Mohamed W. Attwa, Ali S. Abdelhameed, Adnan A. Kadi   +2 more
doaj   +1 more source

Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation

Molecules, 2023
Bosutinib (BOS) is FDA approved drug for the treatment of chronic phase (CP) Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
Mohamed W. Attwa, Mohammed M. Alanazi
doaj   +1 more source